A phase 3 trial comparing tumor-infiltrating cells (TILs) and a checkpoint inhibitor for the treatment of advanced melanoma favored TILs for every end point. The results included a greater than twofold increase in the proportion of patients achieving a complete response.
“For patients with advanced melanoma, we see a 50% reduction in the chance of progression of the disease or dying from the disease, which is absolutely practice-changing,” reported John Haanen, MD, PhD, a research